How People Manage Long COVID Symptoms Using Over-the-Counter Medicines and Other Home Treatments

Declarations. Ethics approval and consent to participate: Ethical approval was obtained from the Solihull Research Ethics Committee, West Midlands (21/WM/0203) as part of the wider Therapies for Long COVID (TLC) Study research program (National Institute for Health and Care Research (NIHR): COV-LT-0013). Both verbal and written explanations of the experimental protocol were provided to the participants. The experimental protocol was developed in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study, which also included consent for data publication. Consent for publication: Not applicable. Competing interests: OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, LifeArc, Innovate UK (part of UK Research and Innovation), The Health Foundation, Gilead Sciences Ltd, Merck, Anthony Nolan, GSK, and Sarcoma UK. He declares personal fees from Gilead Sciences, Merck, Innovate UK, and GSK outside the submitted work. SEH receives funding from the NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham, and Anthony Nolan. SEH declares personal fees from Cochlear Ltd and Aparito Ltd outside the submitted work. CM receives funding from the National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, the NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, CIS Oncology, Innovate UK, Anthony Nolan and has received personal fees from Aparito Ltd outside the submitted work. SH receives funding from NIHR and UKRI. He has received royalties from commercial licenses for the Symptom Burden Questionnaire TM for Long COVID. He has undertaken paid consultancy work for the Phoenix Group. MJC received personal fees from Astellas, Boehringer Ingelheim, Aparito Ltd, CIS Oncology, Gilead, Halfloop, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK, Vertex and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. MJC receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, LifeArc, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, European Regional Development Fund – Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK, Anthony Nolan, and Gilead Sciences. All other authors declare no competing interests.